NRX Pharmaceuticals (NRXP) Net Income towards Common Stockholders (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$5.0 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 29.33% year-over-year to -$5.0 million in Q1 2026; TTM through Mar 2026 was -$17.5 million, a 7.32% decrease from a year earlier, with the FY2025 full-year figure at -$67.4 million, down 168.3% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$5.0 million, down from -$4.6 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for NRXP reached as high as -$2.4 million in Q4 2024 and fell as low as -$16.7 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$6.2 million across 5 years, with a median of -$5.0 million in 2026.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 97.27% in 2022 and fell as far as 1769.83% in 2022.
• Year by year, Net Income towards Common Stockholders stood at -$10.2 million in 2022, then surged by 56.92% to -$4.4 million in 2023, then jumped by 44.97% to -$2.4 million in 2024, then sank by 90.28% to -$4.6 million in 2025, then fell by 7.58% to -$5.0 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$5.0 million in Q1 2026, -$4.6 million in Q4 2025, and -$4.2 million in Q3 2025.